# Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).

> The immune system is stimulated to attack cancer cells with checkpoint inhibitors, whereas checkpoint inhibitors block immune inhibition, and vaccine therapies stimulate the immune system to attackcancer cells with a different effect on survival.

## Metadata
- Authors: L. Gandhi, K. Ramirez, P. Schwarzenberger, T. Ricciardi, M. Macri, A. Ryan, R. Venhaus
- Journal: Journal of Clinical Oncology
- Published: 2018
- DOI: https://doi.org/10.1200/JCO.2018.36.15_SUPPL.TPS9107
- Citations: 13
- Source: Semantic Scholar

## Technology Hub
- Hub: mRNA Therapies
- Discipline: Medicine / Biotechnology
- Hub URL: https://science-database.com/technology/mrna-therapies
- Hub llms.txt: https://science-database.com/technology/mrna-therapies/llms.txt

## Links
- DOI: https://doi.org/10.1200/JCO.2018.36.15_SUPPL.TPS9107
- Semantic Scholar: https://www.semanticscholar.org/paper/70039aca56db47e9d00c0e3adde4e01fa05f8e58
- JSON API: https://science-database.com/api/v1/technology/mrna-therapies

---
Generated by science-database.com — The Knowledge Interface
Paper ID: s2-70039aca56db47e9d00c0e3adde4e01fa05f8e58 | Hub: mrna-therapies